BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

OVID

Ovid Therapeutics Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$733000−88.3% year on year
$8M$5M$3M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$11M−60.1% year on year
$300M$200M$100M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$38M
$200M$100M$0−$100M
Q1 ’21Q2 ’22Q3 ’23Q3 ’24Q4 ’25
Company filings · 10-K filed 18 Mar 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty